Review





Similar Products

apparent diffusion coefficient adc maps  (Philips Healthcare)
86
Philips Healthcare apparent diffusion coefficient adc maps
Apparent Diffusion Coefficient Adc Maps, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient adc maps/product/Philips Healthcare
Average 86 stars, based on 1 article reviews
apparent diffusion coefficient adc maps - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
apparent diffusion coefficient adc  (Takeda)
86
Takeda apparent diffusion coefficient adc
Apparent Diffusion Coefficient Adc, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient adc/product/Takeda
Average 86 stars, based on 1 article reviews
apparent diffusion coefficient adc - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
apparent diffusion coefficient  (Wolters Kluwer Health)
86
Wolters Kluwer Health apparent diffusion coefficient
Apparent Diffusion Coefficient, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient/product/Wolters Kluwer Health
Average 86 stars, based on 1 article reviews
apparent diffusion coefficient - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
apparent diffusion coefficient adc maps  (Bruker Corporation)
97
Bruker Corporation apparent diffusion coefficient adc maps
A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
Apparent Diffusion Coefficient Adc Maps, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient adc maps/product/Bruker Corporation
Average 97 stars, based on 1 article reviews
apparent diffusion coefficient adc maps - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
apparent diffusion coefficient adc images  (Bruker Corporation)
97
Bruker Corporation apparent diffusion coefficient adc images
A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
Apparent Diffusion Coefficient Adc Images, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient adc images/product/Bruker Corporation
Average 97 stars, based on 1 article reviews
apparent diffusion coefficient adc images - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
apparent diffusion coefficient (adc)  (Siemens Healthineers)
90
Siemens Healthineers apparent diffusion coefficient (adc)
A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion <t>coefficient</t> <t>(ADC)</t> observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.
Apparent Diffusion Coefficient (Adc), supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient (adc)/product/Siemens Healthineers
Average 90 stars, based on 1 article reviews
apparent diffusion coefficient (adc) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
apparent diffusion coefficient  (Bruker Corporation)
97
Bruker Corporation apparent diffusion coefficient
Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion <t>coefficient.</t> (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.
Apparent Diffusion Coefficient, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient/product/Bruker Corporation
Average 97 stars, based on 1 article reviews
apparent diffusion coefficient - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
apparent diffusion coefficient  (Staidson BioPharma)
90
Staidson BioPharma apparent diffusion coefficient
Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion <t>coefficient.</t> (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.
Apparent Diffusion Coefficient, supplied by Staidson BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apparent diffusion coefficient/product/Staidson BioPharma
Average 90 stars, based on 1 article reviews
apparent diffusion coefficient - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion coefficient (ADC) observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.

Journal: bioRxiv

Article Title: Multimodal Characterization and Evolution of Malonate-induced Stroke Model: Advanced MRI, Histology-Molecular Profiling

doi: 10.1101/2025.10.22.684053

Figure Lengend Snippet: A. The percentage of viable and necrotic tissue with respect to the total lesion volume. B.The evolution of vessel radius (R). C. Blood volume fraction (BVF). D. Oxygen saturation (StO 2 ) E. Signal enhancement F. Apparent diffusion coefficient (ADC) observed by MRI at D4, D7, D14, D28, and D56 after ischemic injury by malonate injection. n=5 at D4, n=13 at D7, n=8 at D14, n=8 at D28 and n=7 at D56. Data is represented by medians and IQR. *: 0.03>p>0.01, **: 0.005>p>0.001, ***: 0.0005>p>0.0001, ****: p<0.0001 vs contralateral hemisphere, paired non-parametric Mann-Whitney test.

Article Snippet: Apparent diffusion coefficient (ADC) maps were automatically computed on the Bruker scanner as the means of the ADCs observed in each of three orthogonal directions.

Techniques: Diffusion-based Assay, Injection, MANN-WHITNEY

Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.

Journal: Journal for immunotherapy of cancer

Article Title: Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.

doi: 10.1136/jitc-2023-008475

Figure Lengend Snippet: Figure 4 (A and B) MRI and pathological alterations in patients before and after axitinib plus toripalimab administration. (A) Example of highly immune infiltrated tumor; (B) example of minimally infiltrated tumor. ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360. The volcano plot displays differential gene expression at baseline. (D). Relative fraction of tumor-infiltrating lymphocytes. Each row represents an immune cell subpopulation estimated by multiplexed immunofluorescence, including the density of PD1+ cells, PD1+CD8+ cells, PD- L1+ cells, PD-L1+CK+ cells, CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, CD68+CD163- macrophage cells M1, CD68+CD163+ macrophage cells M2. The relative infiltrations of each lymphocyte subpopulations were normalized into a z-score. (E). Comparison of density levels of tumor-infiltrating PD1+ cells, PD1+CD8+ cells, PD-L1+ cells, PD- L1+CK+ cells between partial response (PR) and SD patients. *, p<0.05. (F). Comparison of density levels of tumor-infiltrating CD3+ cells, CD4+ cells, CD8+ cells, CD20+ cells, CD56+ cells, FOXP3+ cells, M1 macrophages, and M2 macrophages between PR and SD patients. No significant differences were found. (G). Representative multiplexed immunofluorescence images showing the simultaneous staining of panel 1 (left): DAPI (blue), CD8+ (red), PD-1+ (green), PD-L1+ (yellow), and CK (gray). Panel 2 (right): DAPI (blue), CD3+ (red), CD4+ (green), FOXP3+ (yellow), CD20+ (orange), and CK (gray) in PR (up) and SD (bottom) patients. Scale bar: 20 µm.

Article Snippet: ADC: apparent diffusion coefficient. (C) Baseline biomarkers correlated with response to treatment analyzed by NanoString IO 360.

Techniques: Diffusion-based Assay, Gene Expression, Immunofluorescence, Comparison, Staining